The percentage of days with genital lesions was also significantly reduced , from 9.0 % in the placebo group to 1.2 % in both the group receiving 75 mg of pritelivir daily ( relative risk , 0.13 ; 95 % CI , 0.02 to 0.70 ) and the group receiving 400 mg weekly ( relative risk , 0.13 ; 95 % CI , 0.03 to 0.52 ) .